obinutuzumab plus chlorambucil
GPTKB entity
Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
combination drug
|
| gptkbp:administeredBy |
intravenous infusion and oral tablet
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:clinicalTrialPhase |
CLL11 study
|
| gptkbp:hasComponent |
gptkb:obinutuzumab
gptkb:chlorambucil |
| https://www.w3.org/2000/01/rdf-schema#label |
obinutuzumab plus chlorambucil
|
| gptkbp:improves |
progression-free survival
|
| gptkbp:indication |
untreated chronic lymphocytic leukemia
|
| gptkbp:mechanismOfAction |
anti-CD20 monoclonal antibody and alkylating agent
|
| gptkbp:sideEffect |
infections
neutropenia thrombocytopenia infusion-related reactions |
| gptkbp:usedFor |
chronic lymphocytic leukemia
|
| gptkbp:bfsParent |
gptkb:ELEVATE-TN
|
| gptkbp:bfsLayer |
7
|